Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

MDS 2020 | EPO plus G-CSF treatment for MDS

Nicolas Bonadies, MD, Bern University Hospital, Bern, Switzerland, discusses the efficacy of combining granulocyte-colony stimulating factor (G-CSF) with erythropoietin (EPO) for low-risk myelodysplastic syndrome (MDS) patients. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.